Background. Reports have found a link between vancomycin treatment failure in methicillin-resistant Staphyloccocus aureus (MRSA) bloodstream infections (BSIs) and higher vancomycin minimum inhibitory concentrations (MICs), despite MICs being below the susceptibility breakpoint of 2 lg/mL. Consensus guidelines recommend considering use of alternative agents for infections involving a higher vancomycin MIC, despite few data to support this approach.
used Etest methods, usually in a comparison of 2 groups, low versus high MIC (ie, ,1.5 vs 1.5-2.0 lg/mL). When comparing groups by vancomycin MIC and using an objective definition of failure, higher failure rates (15% vs 36%; P , .05) were found in strains with a higher vancomycin MIC [4] . Furthermore, a separate investigation found that empirical use of vancomycin for treatment of MRSA BSIs with an MIC of 2 lg/mL was independently associated with mortality (odds ratio [OR] , 6 .39 [95% confidence interval {CI}, 1.68-24.3]) [1] .
Recent consensus guidelines recommend clinicians consider using alternative agents for MRSA infections when the vancomycin MIC is .1 lg/mL [7] . This recommendation is mainly supported by studies reporting poorer outcomes in these infections and by the premise that the likelihood of achieving target vancomycin pharmacodynamic parameters is presumed to be low with a higher vancomycin MIC. However, to our knowledge, there are no clinical data to support an improved outcome with alternative agents when the vancomycin MIC is higher, which presents a therapeutic conundrum for clinicians. Daptomycin, a lipopeptide antibiotic, is approved by the US Food and Drug Administration for the treatment of S. aureus BSIs, including those with right-sided endocarditis, and is considered a reasonable alternative to vancomycin. A large, prospective, randomized controlled trial found similar success rates when daptomycin was compared with standard treatment (ie, vancomycin plus gentamicin [for 4 days] for MRSA) in S. aureus BSI with or without endocarditis [8] . In the subset of patients with MRSA BSI, the success rates were numerically higher among daptomycin-treated patients, although the differences were not statistically different. A subsequent report evaluating the MRSA isolates from this study found that all strains in the vancomycin arm had MICs #1 lg/mL [9] . Therefore, the question of whether alternative therapy confers a benefit in cases of MRSA BSI with high vancomycin MIC remains unanswered. The purpose of this study was to evaluate the comparative effectiveness of vancomycin and daptomycin in treating MRSA BSIs with a high vancomycin MIC (ie, .1 lg/mL).
METHODS

Study Design, Population, and Matching Criteria
This retrospective case-control study evaluated the effectiveness and safety of vancomycin, compared with that of daptomycin, in the treatment of BSI due to MRSA isolates having a vancomycin MIC that is high (ie, .1 lg/mL) yet still within the susceptibility range designated by the CLSI (ie, #2 lg/mL). Subjects with MRSA BSI who were hospitalized over a 5-year period (2005) (2006) (2007) (2008) (2009) ) at a 900-bed tertiary care hospital in Detroit, Michigan, were eligible for inclusion. For inclusion, subjects had to (1) have an index MRSA bloodstream isolate with a vancomycin MIC of 1.5 or 2 lg/mL, as determined by Etest (bio-Merieux); (2) receive active therapy within 48 hours after onset of infection; (3) be treated with either vancomycin or daptomycin for $48 hours; (4) receive treatment with daptomycin within 14 days after onset of infection, if switched to daptomycin from other therapy; and (5) be $18 years of age. Subjects with respiratory sources of MRSA were excluded. Consecutive daptomycin-treated subjects were enrolled and matched in a 1:2 ratio to vancomycin-treated subjects. Subjects were matched on the basis of age, Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, and risk level of the source (ie, low, intermediate, or high), as previously described [1, 10] . Daptomycin use was restricted to approval by the infectious diseases service over the study period. This study was approved by the Institutional Review Board at Henry Ford Hospital. Clinical data collection from the medical record was conducted using a standardized case report form.
Data and Definitions
Microbiologic Data
Each MRSA bloodstream isolate underwent routine susceptibility testing by the clinical microbiology laboratory at Henry Ford Hospital. Vancomycin and daptomycin MICs were determined by Etest. Drug Dosing Characteristics All patients received an initial vancomycin dosing regimen that was based on either the hospital-approved dosing nomogram, which has been adapted from a previously validated nomogram to achieve vancomycin trough values of 10-20 lg/mL, or an individualized dosing regimen determined by pharmacy services on the basis of both predicted empirical and calculated pharmacokinetics for definitive treatment [11] . For the purpose of evaluating trough levels, patients undergoing hemodialysis or those with acute renal failure at onset of infection were excluded from the analysis. Vancomycin trough values were obtained from serum concentrations collected within the hour before the next dose at steady-state conditions. The definitive vancomycin trough was determined using the average vancomycin trough concentration obtained at steady-state after the first 72 hours of treatment. Dosing guidelines for daptomycin in the treatment of BSI were 6 mg/kg every 24 hours, with the frequency extended to 48 hours for those with a creatinine clearance rate of ,30 mL/min. Dose increases #12 mg/kg were permitted at the discretion of the treating physician.
Definitions and Outcomes Assessment
The suspected source of the BSI was identified by chart review, using standard definitions for nosocomial infection [12] . The source of BSI was classified into 3 categories: low risk (associated mortality rate, ,10%), which included intravenous catheter, urinary tract, ear-nose-larynx, gynecologic, and several manipulation-related sources; intermediate risk (associated mortality rate, 10%-20%), which included osteoarticular, soft-tissue, and unknown sources; and high risk (associated mortality rate, .20%), which included endovascular, abdominal, and central nervous system sources, as previously described [1, 10] . Patients with .1 possible source were considered to have the higher-risk source. Epidemiologic classification was based on presence or absence of healthcarerelated risk factors and on determination of whether the acquisition was of community or hospital origin, as previously described [13] . Subjects were classified into 3 groups at the time of the switch to daptomycin: no improvement during current therapy, adverse event due to current therapy, or undetermined reason. Subjects were classified as not improving if a majority of their signs and symptoms of infection at baseline had not resolved, if they had worsening signs of infection, or if results of blood cultures were persistently positive at the time of the switch. Duration of bacteremia was calculated as the number of days the blood culture results were documented to be positive. Concomitant therapy was defined as treatment with either aminoglycoside or rifampin for $3 days. Concomitant therapy was classified as early (#48 hours after onset) or late (.48 hours after onset).
To evaluate safety, nephrotoxicity was evaluated in vancomycin-treated subjects and defined as an increase in the serum creatinine level of 0.5 mg/dL or 50%, whichever was greater, on at least 2 consecutive measurements from the initiation of vancomycin to 3 days after treatment [3, 14] . Creatine phosphokinase values were evaluated in daptomycin-treated subjects. A clinically significant elevation was defined as 5 times the upper limit of normal (ie, .850 U/L).
Clinical failure, the primary end point, was defined as a composite of 60-day mortality, microbiologic failure, and/or recurrence of MRSA BSI. Sixty-day mortality was defined as mortality occurring in the 60-day period following index culture. Microbiologic failure for vancomycin-treated subjects was defined as growth of MRSA in blood cultures $7 days after the index culture, during therapy. Microbiologic failure for daptomycin-treated subjects was defined as growth of MRSA in blood cultures $7 days after the initiation of daptomycin. Recurrence of infection was defined as MRSA BSI within 30 days after completion of therapy.
Statistical Analysis
Descriptive characteristics are reported as percentages, mean values 6 standard deviations, or median values with interquartile ranges (IQRs). Although treatment groups were similar on the basis of matching criteria, comparisons were made to determine whether the groups were well matched for other variables. Because of the matched design of the study, the group comparisons were performed using univariable conditional logistic regression modeling. Comparisons were also made between patients with a clinical outcome of failure and patients with clinical success, using univariable conditional logistic regression modeling. To evaluate outcome in a multivariable setting, conditional logistic regression analysis was conducted to determine independent variables associated with clinical failure. Variables associated with outcome having a univariable P value ,.15, as well as any disparate variables identified between the vancomycin and daptomycin groups (defined as those with a P value ,.15), were included in the model. P values ,.05 were considered statistically significant for all comparisons. Kaplan-Meier estimation was used to obtain the 60-day survival curve for each study group, with the start of the follow-up period defined as the original date of isolation (for the vancomycin group) and the daptomycin-initiation date (for the daptomycin group). The log-rank test for survival data was used to compare the 2 curves. Data were analyzed using SAS software, version 9.2 (SAS Institute).
RESULTS
A total of 541 consecutive patients with MRSA BSIs with high vancomycin MICs were identified over the study period, of which 62 (11%) were treated with daptomycin. Three daptomycin-treated subjects were excluded because the time to initiation of daptomycin exceeded 14 days. Control patients were selected and matched from the remaining population. A total of 177 subjects were enrolled in the study, of whom 59 were cases (the daptomycin-treated group), and 118 were controls (the vancomycin-treated group). The groups were similar with regard to matching criteria, with a mean age of approximately 51 years, a mean APACHE-II score of 14, and similar risk sources (22% low risk, 32% intermediate risk, and 46% high risk) ( Table 1 ). The distribution of vancomycin MICs in the overall study population was 72% for MICs of 1.5 lg/mL and 28% for MICs of 2 lg/mL. The distribution of daptomycin MICs were as follows: 0.19 lg/mL, 3%; 0.25 lg/mL, 3%; 0.38 lg/mL, 24%; 0.5 lg/mL, 35%; 0.75 lg/mL, 29%; 1 lg/mL, 6%; and 2 lg/mL, 1%. The 1 daptomycin-nonsusceptible isolate was from a subject in the vancomycin group. Baseline characteristics were similar between groups (Table 1) , with the exception of more chronic kidney disease (6% vs 17%), immunosuppression (13% vs 27%), osteomyelitis (12% vs 24%), and isolates with a vancomycin MIC of 2 lg/mL (14% vs 58%) in the daptomycin group (P , .05 for all comparisons).
Of the 59 daptomycin-treated subjects, 58 (98%) were switched to daptomycin from initial therapy (91% were switched from vancomycin). Median time to switch was 5 days (IQR, 3-9 days). Sixty percent of patients switched to daptomycin were not improving or were worsening during current therapy, with 48% having positive blood culture results at the time of switch. Only 3% were switched because of an adverse event, and in 38% of cases the reason could not be objectively determined. 
Clinical Outcomes
Clinical outcomes were compared between vancomycin-and daptomycin-treated subjects ( Table 2 ). The composite of clinical failure was lower in daptomycin-treated subjects (31% vs 17%; P 5 .084), although this did not achieve statistical significance. Mortality (20% vs 9%; P 5 .046) was significantly lower in daptomycin-treated subjects, while microbiologic failure (9% vs 10%; P 5 .855) and recurrence (6% vs 3%; P 5 .620) were similar between groups. Treatment groups were also stratified by vancomycin MIC and risk level of the source and compared (Table 2) .
Patient, infection, and treatment characteristics were compared by clinical outcome ( between vancomycin-and daptomycin-treated subjects found a higher probability of survival in the daptomycin-treated group (P 5 .022) (Figure 1) . A post hoc analysis was conducted to evaluate the relationship of vancomycin trough values to clinical outcome. Long-term dialysis patients and those with acute renal failure at baseline were excluded, which left 63 evaluable patients. Initial vancomycin trough values were available for 56 subjects. Of these, initial trough values were ,15 lg/mL in 45 subjects (80%) and $15 lg/mL in 11 subjects (20%). The clinical failure rate was compared between those with an initial trough value ,15 lg/mL or and those with an initial trough value $15 lg/mL and was higher in the latter group (16% vs 46%; P 5 .045). Definitive vancomycin trough values were available for 53 subjects. Of these, trough values were ,15 lg/mL in 18 subjects (34%) and $15 lg/mL in 35 subjects (66%). Clinical failure was similar between definitive vancomycin trough groups (22% vs 20%; P . .999).
Safety Evaluation
After exclusion of long-term dialysis subjects and those with acute renal failure at baseline, 63 vancomycin-treated subjects were evaluable for nephrotoxicity. Of these, 13 (21%) experienced nephrotoxicity. Median time from initiation of vancomycin to onset of nephrotoxicity was 5 days (IQR, 2-14). Of 59 daptomycin-treated subjects, 1 (2%) experienced an elevated creatine phosphokinase level, which peaked at 6827 U/L and resolved upon discontinuation of daptomycin.
DISCUSSION
This study evaluated the comparative effectiveness of daptomycin and vancomycin for MRSA BSIs with a vancomycin Abbreviations: BSI, bloodstream infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus. a Clinical failure, the primary end point, was defined as a composite of 60-d mortality, microbiologic failure, and/or recurrence of MRSA BSI.
b Sixty-day mortality was defined as mortality occurring in the 60-d period following the index culture.
c Microbiologic failure for vancomycin-treated subjects was defined as growth of MRSA from blood culture $7 d from the index culture while receiving therapy. Microbiologic failure for daptomycin-treated subjects was defined as growth of MRSA from blood culture $7 d from the initiation of daptomycin. d Recurrence of infection was defined as recurrence of MRSA BSI within 30 days after completion of therapy.
e Infections with a vancomycin MIC of 1.5 lg/mL (n 5 102 for vancomycin and n 5 25 for daptomycin) or 2 lg/mL (n 5 16 for vancomycin, and n 5 34 for daptomycin) were compared. f Comparisons were stratified by risk level of the source of infection. This included low risk (n 5 26 for vancomycin and n 5 13 for daptomycin), intermediate risk (n 5 38 for vancomycin and n 5 19 for daptomycin), and high risk (n 5 54 for vancomycin and n 5 27 for daptomycin). MIC that is high yet still within the susceptible range. Although consensus guidelines recommend consideration of switching to an alternative agent in the setting of a high vancomycin MIC, data supporting this strategy have been lacking. The results of the present study provide the first clinical comparison of alternative therapy in patients with MRSA BSI with a high vancomycin MIC and confirm that vancomycin-treated patients are at high risk for failure; however, this risk is mitigated by treatment with daptomycin. Our findings also suggest that treatment with daptomycin is associated with a survival advantage at 60 days. Earlier studies, which have used varying definitions, report failure rates of 28%-38% in MRSA BSIs with a high vancomycin MIC [1, 3, 4] . The vancomycin failure rate in the present study is consistent with these reports, including a study that reported a failure rate of 36%, using a similar composite definition of failure [4] . Although the study lacked a comparison of outcome by treatment group, the authors reported a lower failure rate (20%) in those switched to an alternative antibiotic, which is similar to the 17% failure rate we observed in the daptomycin group. These findings have important implications in the management of serious MRSA infection.
The reason for improved outcome with daptomycin in this study is unclear. However, it could be related to daptomycin's bactericidal activity against S. aureus, which may become particularly important when strains exhibit higher vancomycin MICs [15] . Importantly, there were several reasons why daptomycintreated patients might actually fare worse than those treated with vancomycin. For instance, the daptomycin group had more isolates with a vancomycin MIC of 2 lg/mL. This likely indicates that a level of selection bias existed, as patients not improving, or those with an isolate at the higher end of the susceptibility range, are commonly switched to another agent during routine management. These patients are generally considered at higher risk for failure, yet despite this, the daptomycin group still had improved outcomes. Also, earlier studies have suggested that prior vancomycin exposure can decrease in vitro susceptibility to both vancomycin and daptomycin [16, 17] . In the present study, although most patients in the daptomycin group were switched from vancomycin, it does not appear this was a factor influencing outcome. It has been shown that daptomycin maintains good in vitro activity against isolates of S. aureus with a vancomycin MIC of 2 lg/mL and that the prevalence of resistance to daptomycin is low in these isolates [18] . In this study, therapy was changed to daptomycin in most patients because they were worsening or not improving during current therapy. This delay in the initiation of daptomycin could have been associated with a poorer outcome; however, no association with outcome was noted. Importantly, the findings of the present study also confirm the approach recommended by the recent Infectious Diseases Society of America clinical practice guidelines for the treatment of MRSA, which suggest changing to an alternative agent in patients who have not clinically responded to vancomycin [19] .
Recent single and multicenter studies have shown the prevalence of MRSA with higher vancomycin MICs to be as high as 90%, with a recent 9-hospital surveillance study finding 58% with an MIC of 1.5 lg/mL and 32% with an MIC of 2 lg/mL [5, 20] . This underscores the significant impact these findings may have in the management of MRSA BSIs. The determination of vancomycin MIC is method specific. The Etest method usually reports MICs that are slightly higher than those of other methods, highlighting the significant intermethod discordance that can exist [5, 6] . MICs will vary by method of susceptibility testing, institution, and geographic location [5, 20] . In clinical practice, although patients with isolates that have a higher vancomycin MIC may benefit from the switch to daptomycin, it may be more difficult to identify these patients when using other methods for susceptibility testing. Ultimately, in susceptible MRSA, the clinical response should guide management, with prompt change to alternative therapy in patients lacking a clinical or microbiological response to vancomycin.
This study was conducted at a single institution and was of a retrospective nature, which may limit its generalizability to other settings. These results will require validation in a prospective, randomized, controlled comparative efficacy trial, which is currently under way (ClinicalTrials.gov identifier NCT01287832). As most patients in this study were switched to daptomycin from prior therapy, these results may not be generalizable to patients treated empirically with daptomycin. Strengths of this study were that subjects were well matched by severity of illness, infection source, and age and that improved outcome with daptomycin persisted after control for multiple variables, which reduced the impact of confounding. Other strengths include the comprehensive and comparative evaluation of a large number of patients in a geographic area known to be significantly impacted by MRSA, where the first reports of MRSA, and vancomyin-resistant S. aureus, emerged [21] [22] [23] [24] .
The results of this study show that daptomycin is associated with a better outcome in MRSA BSIs for treatment of strains with higher vancomycin MICs and that treatment with daptomycin is associated with a higher probability of survival at 60 days. These findings support the recommendations of recent guidelines that suggest consideration of a switch to alternative agents when the isolate has a high vancomycin MIC or if patients are not improving during current therapy. The combination of high failure rates in vancomycin-treated patients and lower failure rates in daptomycin-treated patients, along with increases in isolates with higher vancomycin MICs, underscores the impact of these findings.
Notes
